About Steril-Gene Life Sciences Private Limited
Data last updated:
Steril-Gene Life Sciences Private Limited is a private limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 February 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN U02423TN2007PTC062549. Its GSTIN is 33AAKCS9783R1Z6 (Tamil Nadu). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹216 Cr and a paid-up capital of ₹212.64 Cr. It was formerly known as Sterigene Life Sciences Private Limited. It is led by directors including Sulaiman Abdulhai Mohammed (Managing Director) and Chanpreet Singh Anand (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at New No.15 Old No.7 Gopalakrishnan Road T. Nagar, Chennai, Tamil Nadu, India – 600017.
As per the financials filed for FY 2025, the company reported a revenue of ₹404.06 Cr, a growth of 41% compared to the previous year. For the same year it recorded a net profit of ₹58.36 Cr (net margin 14.4%) and EBITDA of ₹97.8 Cr (EBITDA margin 24.2%). Revenue has grown at a compounded annual rate (CAGR) of 30% over three years and 34% over five years.
The company has about 957 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Steril-Gene. As per MCA filings, the company has open charges of ₹374.75 Cr and satisfied charges of ₹148.02 Cr on record. The company has 16 deals on record (9 funding rounds, 6 secondary share transfers, 1 rights issue), with disclosed funding of ₹347.93 Cr; the latest was in November 2022. Its 7 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 3 smaller; the largest is Skymap Pharmaceuticals Private Limited with revenue of ₹409.08 Cr. The company has 2 MSME Form 1 returns on record between 2019 and 2024, listing 41 overdue payments to 6 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website steril-gene.com.
Company details
Contact details
Steril-Gene Life Sciences Private Limited's registered office is in Chennai, Tamil Nadu. Its website is steril-gene.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressNew No.15 Old No.7 Gopalakrishnan Road T. Nagar, Chennai, Tamil Nadu, India – 600017
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Steril-Gene Life Sciences Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Steril-Gene Life Sciences operates one associated brand: Steril-Gene. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers contract development, manufacturing, and technology transfer for pharmaceuticals globally. | steril-gene.com |
Business activity
The main business activity of Steril-Gene Life Sciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Steril-Gene Life Sciences Private Limited, buy the company report.
Financials of Steril-Gene Life Sciences Private Limited
FY 2024 filings availableSteril-Gene Life Sciences Private Limited reported revenue of ₹404.06 Cr (up 41% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 34% over five years, including 41% growth in the latest year. EBITDA rose 65% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹97.8 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹58.36 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 24.2% | ||||
| Net Profit Margin | 14.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Steril-Gene Life Sciences Private Limited, buy the company report.
Board of directors of Steril-Gene Life Sciences Private Limited
Steril-Gene Life Sciences has 11 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Alagappan Also directs: Anphar Organics Private Limited., Maral Health Care Private Limited, Madras Pharmaceuticals Private Limited and 2 more | Director | 10 Mar 2014 | 12 Years 7 Months | Current |
| Lloyd Dizon Balajadia Also directs: Excipients House LLP, International Ingredients & Excipients Private Limited, Lloyd Research Centre Private Limited and 1 more | Director | 04 Dec 2009 | 16 Years 10 Months | Current |
| Dennis Dizon Balajadia Also directs: Lloyd Laboratories Private Limited | Director | 04 Dec 2009 | 16 Years 10 Months | Current |
| Sulaiman Abdulhai Mohammed Also directs: Pulmocare Lifesciences India Private Limited, Anphar Organics Private Limited., Softgel Healthcare Private Limited and 5 more | Managing Director | 28 Feb 2007 | 19 Years 8 Months | Current |
| Dick Dizon Balajadia | Director | 04 Dec 2009 | 16 Years 10 Months | Current |
| Manohar Srivignesh | Director | 14 Dec 2023 | 2 Years 10 Months | Current |
Peer comparison
Steril-Gene Life Sciences Private Limited is compared with the 7 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Skymap Pharmaceuticals Private Limited | ₹409.08 Cr (FY 2025) | 2.0% | New Delhi, Delhi, India | |||
| Arene Life Sciences (Unit 4) Private Limited | ₹405.87 Cr (FY 2021) | 3.0% | Hyderabad, Telangana, India | |||
| United Biotech Private Limited | ₹404.94 Cr (FY 2024) | 27.0% | New Delhi, Delhi, India | |||
| Torque Pharmaceuticals Private Limited | ₹404.13 Cr (FY 2024) | 1.0% | Chandigarh, India | |||
| Steril-Gene Life Sciences Private Limitedthis company | ₹404.06 Cr (FY 2025) | ₹58.36 Cr | 14.4% | 41.0% | 957 | Chennai, Tamil Nadu, India |
| Zeiss Pharmaceuticals Private Limited | ₹403.65 Cr (FY 2025) | 6.0% | Nalagarh, Himachal Pradesh, India | |||
| Gland Chemicals Pvt Ltd | ₹401.18 Cr (FY 2022) | 33.0% | Hyderabad, Telangana, India | |||
| Maiva Pharma Private Limited | ₹399.05 Cr (FY 2025) | 38.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Steril-Gene Life Sciences Private Limited, buy the company report.
Auditor
Steril-Gene Life Sciences Private Limited is audited by S.R. Batliboi & Associates Llp for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates Llp | FY 2023 | 101049W/E300004 |
Shareholding
The shareholding of Steril-Gene Life Sciences Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Steril-Gene Life Sciences Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Jan 2025 | 101043873 | Hdfc Bank Limited | ₹20 Cr | Open | |
| 17 May 2024 | 100923262 | Hdfc Bank Limited | ₹30 Cr | Open | |
| 09 Jun 2023 | 100740781 | Hdfc Bank Limited | ₹120 Cr | Open | |
| 17 Apr 2023 | 100710890 | Hdfc Bank Limited | ₹5 Cr | Open | |
| 17 Apr 2023 | 100710862 | Hdfc Bank Limited | ₹9 Cr | Open |
To see the full charge records of Steril-Gene Life Sciences Private Limited, buy the company report.
Total charge records: 15 View all charges
Deals & funding
Steril-Gene Life Sciences Private Limited has 16 deals on record (9 funding rounds, 6 secondary share transfers, 1 rights issue), with disclosed funding of ₹347.93 Cr; the latest was in November 2022.
Deals on record (5 of 16)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2019 | Secondary share transfer | Undisclosed | Buyer: Softgel Healthcare Private Limited Seller: Accent Pharma & A.m Sulaiman |
| Feb 2018 | Secondary share transfer | Undisclosed | Buyer: Softgel Healthcare Private Limited Seller: Accent Pharma & A.m Sulaiman |
| Jun 2011 | Funding round | ₹24.99 Cr | Investors: Lloyd Laboratories Inc, Star Trend Holdings Corp., Accent Pharma & A.m Sulaiman |
| Jul 2010 | Secondary share transfer | Undisclosed | Buyer: Madras Pharma Holdings Private Limited , Accent Pharma & A.m Sulaiman Seller: The Madras Pharmaceuticals & Am Sulaiman, 3 individuals |
| Nov 2009 | Funding round | ₹68.7 Cr | Investors: Star Trend Holdings Corp., Accent Pharma & A.m Sulaiman, Madras Pharma Holdings Private Limited |
To see the full deal history of Steril-Gene Life Sciences Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Steril-Gene Life Sciences Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Steril-Gene Life Sciences Private Limited has 2 MSME Form 1 returns on record between 2019 and 2024, listing 41 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 6)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Air Calibre Systems | |||
| A to Z Lab Need | |||
| an individual supplier | |||
| Alcon Biosciences Private Limited | |||
| Aic Specialities |
To see the full MSME payment records of Steril-Gene Life Sciences Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Steril-Gene Life Sciences Private Limited has a workforce of 957 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.
GST
Steril-Gene Life Sciences has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAKCS9783R1Z6 | Tamil Nadu | Active | 02 Nov 2021 |
| 34AAKCS9783R1Z4 | Puducherry | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Steril-Gene Life Sciences Private Limited, buy the company report.
Recent activity
Steril-Gene Life Sciences Private Limited has 27 board changes on record since 2007: 11 appointments and 16 cessations. The latest: Manohar Srivignesh ceased to be Additional Director on 29 Sep 2024.
53 earlier events are in the company report.
Frequently asked questions
Steril-Gene Life Sciences is an active private limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 February 2007 (19+ years old) and is registered under CIN U02423TN2007PTC062549.
Steril-Gene Life Sciences has 11 current directors:
- Sulaiman Abdulhai Mohammed - Managing Director
- Chanpreet Singh Anand - Whole-Time Director
- Alagappan - Director
- Lloyd Dizon Balajadia - Director
- Dennis Dizon Balajadia - Director
- Dick Dizon Balajadia - Director
- Manohar Srivignesh - Director
- Zenaida Dizon Balajadia - Director
- Nagappan Kannappan - Director
- Maximo Ponce Balajadia - Director
- Vijay Balakumar - Director
The latest financial statements of Steril-Gene Life Sciences on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Steril-Gene Life Sciences is 33AAKCS9783R1Z6, registered in Tamil Nadu. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 34AAKCS9783R1Z4 (Puducherry).
The CIN (Corporate Identification Number) of Steril-Gene Life Sciences is U02423TN2007PTC062549. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Steril-Gene Life Sciences was incorporated on 28 February 2007, making it 19+ years old. It is registered with the Registrar of Companies, Chennai.
Steril-Gene Life Sciences has 16 deals on record (9 funding rounds, 6 secondary share transfers, 1 rights issue), with disclosed funding of ₹347.93 Cr; the latest was in November 2022.
The peers of Steril-Gene Life Sciences by revenue are Skymap Pharmaceuticals Private Limited, Arene Life Sciences (Unit 4) Private Limited, United Biotech Private Limited, Torque Pharmaceuticals Private Limited, Zeiss Pharmaceuticals Private Limited and 2 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Manohar Srivignesh ceased to be Additional Director on 29 Sep 2024. Vijay Balakumar ceased to be Additional Director on 29 Sep 2024. Manohar Srivignesh was appointed as Director on 14 Dec 2023. Steril-Gene Life Sciences has 27 board changes on record in total.
Steril-Gene Life Sciences has 2 MSME Form 1 returns on record between 2019 and 2024, listing 41 overdue payments to 6 micro and small suppliers. The latest return was filed on 24 Jun 2024.
Steril-Gene Life Sciences can be reached through the website steril-gene.com. Its registered office is in Chennai, Tamil Nadu, India.
The registered office of Steril-Gene Life Sciences is at New No.15 Old No.7 Gopalakrishnan Road T. Nagar, Chennai, Tamil Nadu, India – 600017.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
